2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2657

Assessment of Habitual Physical Activity and Performance during Maximal Exercise Test in Systemic Lupus Erythematosus Patients
Abstract Number: 2658

Real World Medication Use in Incident Systemic Lupus Erythematosus and Lupus Nephritis Patients
Abstract Number: 2659

Clinical Features, Damage Accrual and Survival in Patients with Familial Systemic Lupus Erythematosus (SLE): Data from a Multiethnic, Multinational Latin American Lupus Cohort
Abstract Number: 2660

Low-Dose Interleukin-2 Treatment of Refractory Lupus Nephritis
Abstract Number: 2661

Metformin Combined with Conventional Therapy Increases Absolute Number of Regulatory T Cells in Patients with Systemic Lupus Erythematosus
Abstract Number: 2662

Changes in Blood Pressure and Proteinuria at One Year in Two Lupus Nephritis Clinical Trials
Abstract Number: 2663

Comparison of Clinical and Laboratory Profiles in 3575 Systemic Lupus Erythematosus Patients with and without Sjögren’s Syndrome: Data from the Spanish Society for Rheumatology Lupus Registry
Abstract Number: 2664

Long-Term Clinical Outcomes in a Cohort of Adults with Childhood-Onset Systemic Lupus Erythematosus
Abstract Number: 2665

Treatment Trends of Systemic Lupus Erythematosus during Early-Years of the Disease
Abstract Number: 2666

Trends in Treatment of Systemic Lupus Erythematosus and Lupus Nephritis: 2006-2016
Abstract Number: 2667

Sledai and Mex-Sledai Glucocorticoid Indices As Predictors of Damage and Mortality in Multinational Multiethnic Latin American Cohort
Abstract Number: 2668

Hydroxychloroquine and the Risk of Thrombotic Events in Systemic Lupus Erythematosus Patients : A Systematic Review and Meta-Analysis
Abstract Number: 2669

Assessing the Need for Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis in SLE Patients on Immunosuppression
Abstract Number: 2670

Association of Hydroxychloroquine Use and Incident Atrial Fibrillation in Systemic Lupus Erythematosus: A Retrospective Study
Abstract Number: 2671

Development and First-in-Human Characterization of an ICOSL and BAFF Bispecific Inhibitor AMG 570 for SLE Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].